“Global Dermatological Drugs Market Set to Grow To $36bn by 2024”, according to Visiongain

World News: . []

Visiongain has launched a new pharma report : Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan and Other Companies

Dermatological drugs market has been growing over the last decade. A combination of significant new market launches and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain’s analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.

The lead analyst of the report commented “The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas. Although, the development of biological therapies has changed this perception somewhat, it remains likely that future dermatological drug development will be driven by innovation from small biopharmaceutical companies. Many of the novel products in the development pipeline have come from small companies targeting new treatment pathways or mechanisms of action. We note however that the dermatological drugs market is a diverse one, which presents opportunities for large pharma companies also. Development of biologic therapies in this market may be a lucrative business opportunity for big pharma companies over the next decade. One way into the market will be to license pipeline candidates from smaller companies. This is already a common strategy in this sector of the market, and within the pharma industry. Alternatively, a strategy of targeted acquisitions provides opportunities for larger pharmaceutical companies to enter into the dermatological drugs market.”

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on 020 7549 9987

Leading companies featured in the report include Abbvie Inc., Allergan plc, Almirall S.A., Amgen, Astellas, Bayer, Concert Pharmaceuticals, Eli Lilly and Company, Galderma, GlaxoSmithkline plc (GSK), Johnson & Johnson (J&J), Leo Pharma A/S, Lupin Ltd and other companies.

Related reports:

   

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on 020 7549 9987

More news and information about Visiongain Ltd

Published By:

Globe Newswire: 11:41 GMT Wednesday 15th May 2019

Published: .

Search for other references to "global" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us